Novo Nordisk's semaglutide portfolio generated approximately $21.3 billion in net sales in 2024, with Wegovy alone surpassing $4.7 billion in the United States and continuing to grow at annual rates exceeding 70%
In addition, given that most non-clinical studies evaluating the anti-stroke effects of GLP-1RAs were performed in animal models of acute ischemic stroke, in which GLP-1 or its analogues were administered before, during, or after stroke induction, the mechanistic effects of GLP-1RAs in preventing stroke on the long-term need further investigation
A study published in May 2024 found that men with obesity who were taking semaglutide, the active ingredient in Ozempic and Wegovy, were actually at a slightly higher risk of erectile dysfunction than men with obesity who werent taking the drug
Your doctor will suggest over-the-counter medications for nausea, vomiting, and constipation, if needed
J., Lambert, E